Article
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
The oncologist - 1 Jan 2010
Lehmann-Che Jacqueline, André Fabrice, Desmedt Christine, Mazouni Chafika, Giacchetti Sylvie, Turpin Elisabeth, Espié Marc, Plassa Louis-François, Marty Michel, Bertheau Philippe, Sotiriou Christos, Piccart Martine, Symmans W Fraser, Pusztai Lajos, de Thé Hugues
Abstract excerpt
The predictive value of p53 for the efficacy of front-line anthracycline-based chemotherapy regimens has been a matter of significant controversy. Anthracyclines are usually combined with widely different doses of alkylating agents, which may significantly modulate tumor response to these combinations. We analyzed three series of de novo stage II-III breast cancer patients treated front line with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.